HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $52

HC Wainwright & Co. analyst Swayampakula Ramakanth has maintained a 'Buy' rating on Eton Pharmaceuticals (NASDAQ: ETON) and raised the price target from $37 to $52. This adjustment reflects a positive outlook on the company's performance.